Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$67.12 ▲ +0.22
(+0.33%)
MKT CAP: $2.33B • VOL: 991.4K
52W L $60 52W H $156
TMDX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $605.5M | $441.5M | $241.6M |
| YoY Revenue Growth % | +37.1% | +82.7% | — |
| Gross Profit | $362.8M | $262.1M | — |
| Gross Margin % | 59.9% | 59.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $108.6M | $37.5M | -$28.7M |
| Operating Margin % | 17.9% | 8.5% | -11.9% |
| Net Income (GAAP) | $190.3M | $35.5M | -$25.0M |
| EBITDA (Normalized) | $156.0M | $141.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $192.8M | $48.8M | -$13.0M |
| Capital Expenditures (CapEx) | $59.3M | $129.7M | — |
| Free Cash Flow (FCF) | $133.6M | -$80.9M | -$13.0M |
| FCF Margin % | 22.1% | -18.3% | -5.4% |
| Return on Invested Capital (ROIC %) | 18.1% | 13.0% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $473.1M | $228.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TMDX.